Anthralin
As of the edition of 20 October 2026, Anthralin is a small molecule: marketed, first approved in 2016 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Small molecule
- First approved
- 23 March 2016 (CH)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Boiron
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Boiron | Applicant | 2016 to now |